Literature DB >> 11581195

Long-term outcome and predictor variables in the treatment of acquired esotropia with botulinum toxin.

J Tejedor1, J M Rodríguez.   

Abstract

PURPOSE: To determine the long-term results of botulinum therapy in acquired esotropia and to identify predictors of a satisfactory outcome.
METHODS: Sixty-eight children (age range, 8-64 months) with acquired esotropia were enrolled in a prospective study. Botulinum toxin A was injected in the two medial recti. Motor and sensory statuses were evaluated at 1 and 2 weeks; 3, 6, and 12 months; and every year after the last injection. Univariate and multivariate logistic regression analyses were performed to relate motor and sensory outcome to variables recorded as potential predictors.
RESULTS: After an average follow-up of 4.8 years since the last injection, motor success was obtained in 36 children with one injection (52.9%), increasing to 48 (70.6%) and 60 (88.2%) children after two and three injections, respectively. Forty-eight (70.6%) patients had at least peripheral fusion (category 1 binocularity) and 32 (47.1%) had stereoacuity of at least 400 seconds of arc (category 2 binocularity). Higher hypermetropia, less severe amblyopia, and a smaller angle of esotropia were the best predictors of motor success. Minimal amblyopia and favorable motor alignment were associated with better binocularity outcome.
CONCLUSIONS: Botulinum is an effective long-term treatment of acquired esotropia. It is especially useful in children with high hypermetropia, minimal amblyopia, and small esotropic deviation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11581195

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  9 in total

1.  Acute and long-term effects of botulinum neurotoxin on the function and structure of developing extraocular muscles.

Authors:  Scott A Croes; Larisa M Baryshnikova; Soniya S Kaluskar; Christopher S von Bartheld
Journal:  Neurobiol Dis       Date:  2007-01-10       Impact factor: 5.996

2.  Botulinum toxin injections combined with or without sodium hyaluronate in the absence of electromyography for the treatment of infantile esotropia: a pilot study.

Authors:  J Chen; D Deng; H Zhong; X Lin; Y Kang; H Wu; J Yan; G Mai
Journal:  Eye (Lond)       Date:  2012-12-14       Impact factor: 3.775

3.  Increasing muscle strength as a treatment for strabismus: sustained release of insulin-like growth factor-1 in rabbit extraocular muscle.

Authors:  Linda K McLoon; Brian C Anderson; Stephen P Christiansen
Journal:  J AAPOS       Date:  2006-10       Impact factor: 1.220

4.  Extraocular muscle force generation after ricin-mAb35 injection: implications for strabismus treatment.

Authors:  Stephen P Christiansen; Bryan A Becker; Paul A Iaizzo; Linda K McLoon
Journal:  J AAPOS       Date:  2003-02       Impact factor: 1.220

5.  Botulinum toxin pretreatment augments the weakening effect of injection with ricin-mAb35 in rabbit extraocular muscle.

Authors:  Stephen P Christiansen; Brian C Anderson; Linda K McLoon
Journal:  J AAPOS       Date:  2008-02-07       Impact factor: 1.220

Review 6.  Botulinum toxin for the treatment of strabismus.

Authors:  Fiona J Rowe; Carmel P Noonan
Journal:  Cochrane Database Syst Rev       Date:  2017-03-02

7.  Short-term outcome of botulinum neurotoxin A injection with or without sodium hyaluronate in the treatment of infantile esotropia-a prospective interventional study.

Authors:  Nitika Pandey; Siddharth Agrawal; Rajat M Srivastava; Vinita Singh
Journal:  Indian J Ophthalmol       Date:  2020-08       Impact factor: 1.848

8.  Botulinum Toxin Injection with Conjunctival Microincision for the Treatment of Acute Acquired Comitant Esotropia and Its Effectiveness.

Authors:  Hongjia Xu; Weifeng Sun; Shuying Dai; Yanyan Cheng; Jing Zhao; Yuan Liu; Juan Wang; Ya'nan Wang; Yu Gao; Huifang Han; Aijun Han
Journal:  J Ophthalmol       Date:  2020-12-31       Impact factor: 1.909

9.  Treatment of acute acquired concomitant esotropia.

Authors:  Minghua Shi; Yuanxiang Zhou; Aijiao Qin; Jing Cheng; Hongxing Ren
Journal:  BMC Ophthalmol       Date:  2021-01-06       Impact factor: 2.209

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.